Page last updated: 2024-10-16

beta-alanine and Glaucoma

beta-alanine has been researched along with Glaucoma in 14 studies

Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)

Research Excerpts

ExcerptRelevanceReference
" In this study, we conducted a systematic literature review and meta-analysis to summarize and synthesize the available evidence on the efficacy and safety of fixed-dose combination (FDC) therapy with netarsudil/latanoprost in patients with glaucoma."9.22Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. ( Ahn, HS; Chang, DJ; Chang, J; Kang, HY; Lee, H; Lee, JW; Suh, JK, 2022)
"Initial treatment of glaucoma commonly involves using anti-glaucoma medications either as monotherapy or combination therapy."6.66New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. ( Mehran, NA; Razeghinejad, R; Sinha, S, 2020)
" In this study, we conducted a systematic literature review and meta-analysis to summarize and synthesize the available evidence on the efficacy and safety of fixed-dose combination (FDC) therapy with netarsudil/latanoprost in patients with glaucoma."5.22Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. ( Ahn, HS; Chang, DJ; Chang, J; Kang, HY; Lee, H; Lee, JW; Suh, JK, 2022)
"Initial treatment of glaucoma commonly involves using anti-glaucoma medications either as monotherapy or combination therapy."2.66New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. ( Mehran, NA; Razeghinejad, R; Sinha, S, 2020)
"These cataracts were overall small, 1 to 3 mm, round, oval or ring-shaped, central or paracentral with mild density."1.72Anterior Subcapsular Cataract Formation With Long-term Topical Netarsudil Treatment for Glaucoma. ( Chang, EL; Emmel, DK; Liu, J; Sarrafpour, S; Teng, CC, 2022)
"Presence of punctal stenosis after topical netarsudil use and resolution of punctal stenosis after cessation of therapy."1.72Punctal Stenosis Associated with Topical Netarsudil Use. ( Chen, PP; Meirick, TM; Mudumbai, RC; Zhang, MM, 2022)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (28.57)24.3611
2020's10 (71.43)2.80

Authors

AuthorsStudies
Shiuey, EJ1
Mehran, NA2
Ustaoglu, M1
Zhang, Q1
Razeghinejad, R3
Shukla, AG1
Kolomeyer, NN2
Myers, JS2
Lee, D2
Chang, EL1
Emmel, DK1
Teng, CC1
Sarrafpour, S1
Liu, J1
Meirick, TM1
Mudumbai, RC1
Zhang, MM1
Chen, PP1
Jeang, LJ1
Shah, AS1
Hammer, JD1
Tuli, SS1
Goergen, NS1
Gagrani, M1
Gulati, V1
Ghate, D1
Lee, JW1
Ahn, HS1
Chang, J1
Kang, HY1
Chang, DJ1
Suh, JK1
Lee, H1
Bonardi, A1
Supuran, CT1
Sinha, S2
Ostler, E1
Rhee, D1
Burney, E1
Sozeri, Y1
Mehta, AA1
Kanu, LN1
Sood-Mendiratta, S1
Quinones, R1
Hawkins, A1
Lehrer, RA1
Malhotra, K1
Papas, R1
Hillman, D1
Wilensky, JT1
Aref, AA1
Vajaranant, TS1
Edward, DP1
Schehlein, EM1
Robin, AL1
Shaw, PX1
Sang, A1
Wang, Y1
Ho, D1
Douglas, C1
Dia, L1
Goldberg, JL1

Reviews

5 reviews available for beta-alanine and Glaucoma

ArticleYear
Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis.
    Korean journal of ophthalmology : KJO, 2022, Volume: 36, Issue:5

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocula

2022
Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension.
    Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:1

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Drug Combinations; Female; Glaucoma; Humans; Intra

2020
New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.
    Eye (London, England), 2020, Volume: 34, Issue:1

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocula

2020
Advances in medical therapy for glaucoma.
    Current opinion in ophthalmology, 2021, Mar-01, Volume: 32, Issue:2

    Topics: Administration, Ophthalmic; Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma; Humans; Intr

2021
Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment.
    Drugs, 2019, Volume: 79, Issue:10

    Topics: Animals; Benzoates; beta-Alanine; Drug Therapy, Combination; Eye; Glaucoma; Humans; Intraocular Pres

2019

Other Studies

9 other studies available for beta-alanine and Glaucoma

ArticleYear
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2022, Volume: 260, Issue:3

    Topics: Aged; Aged, 80 and over; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocula

2022
Anterior Subcapsular Cataract Formation With Long-term Topical Netarsudil Treatment for Glaucoma.
    Journal of glaucoma, 2022, 01-01, Volume: 31, Issue:1

    Topics: Benzoates; beta-Alanine; Cataract; Glaucoma; Humans; Intraocular Pressure

2022
Punctal Stenosis Associated with Topical Netarsudil Use.
    Ophthalmology, 2022, Volume: 129, Issue:7

    Topics: Benzoates; beta-Alanine; Constriction, Pathologic; Eyelid Diseases; Glaucoma; Humans; Lacrimal Duct

2022
Reticular epithelial edema after penetrating keratoplasty in a patient taking netarsudil.
    Digital journal of ophthalmology : DJO, 2022, Volume: 28, Issue:8

    Topics: Aged; Benzoates; beta-Alanine; Edema; Female; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pr

2022
Pragmatic adjunctive usage of netarsudil: A retrospective chart review from a tertiary care center.
    Indian journal of ophthalmology, 2022, Volume: 70, Issue:8

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Female; Glaucoma; Glaucom

2022
Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595.
    Expert opinion on therapeutic patents, 2019, Volume: 29, Issue:10

    Topics: Benzoates; beta-Alanine; Glaucoma; Humans; Intraocular Pressure; Isoquinolines; Ocular Hypertension;

2019
Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma.
    European journal of ophthalmology, 2022, Volume: 32, Issue:1

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Cohort Studies; Glaucoma; Glaucoma, Open-Angle; Hu

2022
Two new drugs for glaucoma.
    The Medical letter on drugs and therapeutics, 2018, 07-16, Volume: 60, Issue:1551

    Topics: Benzoates; beta-Alanine; Drug Approval; Glaucoma; Humans; Ophthalmic Solutions; Prostaglandins F, Sy

2018
Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury.
    Experimental eye research, 2017, Volume: 158

    Topics: Administration, Topical; Animals; Axons; Benzoates; beta-Alanine; Blotting, Western; Cell Survival;

2017